Research Article
Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure
Table 2
Clinical characteristics according to the upper limit normal plasma PTX3 levels
in CHF patients.
| | | PTX3 <3.64 ng/mL
() | PTX3 ≥3.64 ng/mL
() | value |
| | Age (years) | | | 0.412 | | Males, (%) | 116 (56.6) | 104 (60.5) | 0.464 | | Heart rate, beats/min | | | 0.346 | | NYHA class >II, (%) | 123 (60) | 143 (83.1) | <0.001 | | CHD, (%) | 103 (50.2) | 93 (54.1) | 0.471 | | Diabetes mellitus (%) | 22 (10.7) | 30 (17.4) | 0.072 | | Hypertension, (%) | 83 (40.6) | 60 (34.9) | 0.287 | | Hyperlipidemia, (%) | 50 (24.4) | 44 (25.6) | 0.812 | | Current smoking, (%) | 60 (29.3) | 55 (32.0) | 0.577 | | cTnI (ng/mL) | | | <0.001 | | hsCRP (ng/mL) | | | <0.001 | | Medical therapy | | | | | Aspirin, (%) | 189 (92.2) | 160 (93.0) | 0.845 | | β-blockers, (%) | 142 (69.3) | 112 (65.1) | 0.440 | | ACE-I/ARB, (%) | 151 (73.7) | 115 (66.9) | 0.174 | | Diuretics, (%) | 185 (90.2) | 159 (92.4) | 0.471 |
|
|
Normal PTX3 levels are determined based on the upper limit of plasma PTX3 levels from the mean 2 SD value in 64 control subjects ( ng/mL).
|
